[
    [
        {
            "time": "2018-04-09",
            "original_text": "Top Trending: Chevron backs out of Anadarko deal, Novartis purchases Takeda Eye, Walmart manager salaries",
            "features": {
                "keywords": [
                    "Novartis",
                    "Takeda",
                    "Eye",
                    "purchase",
                    "deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Trending: Chevron backs out of Anadarko deal, Novartis purchases Takeda Eye, Walmart manager salaries",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal",
            "features": {
                "keywords": [
                    "Novartis",
                    "Takeda",
                    "Eye",
                    "Drug",
                    "Deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis to Buy Takeda's Eye Drug in $5.3 Billion Deal",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-11",
            "original_text": "Novartis’s $5.3 Billion Eye Disease Deal Adds Cash for Bigger Bets",
            "features": {
                "keywords": [
                    "Novartis",
                    "Eye",
                    "Disease",
                    "Deal",
                    "Cash"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis’s $5.3 Billion Eye Disease Deal Adds Cash for Bigger Bets",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-12",
            "original_text": "Codexis Bags Novartis as Software Customer, Stays Course in First Quarter",
            "features": {
                "keywords": [
                    "Codexis",
                    "Novartis",
                    "Software",
                    "Customer"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Codexis Bags Novartis as Software Customer, Stays Course in First Quarter",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-13",
            "original_text": "The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",
            "features": {
                "keywords": [
                    "Novartis",
                    "Biotech",
                    "Shopping",
                    "Trial",
                    "Results"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Novartis Goes Shopping, Mixed Trial Results For Provention Bio, 4 Stocks To Debut",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-14",
            "original_text": "Stocks making the biggest moves premarket: Disney, Intel, Etsy, Fox Corp, Costco, Novartis & more",
            "features": {
                "keywords": [
                    "Disney",
                    "Intel",
                    "Etsy",
                    "Fox",
                    "Corp",
                    "Costco",
                    "Novartis"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "various"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Stocks making the biggest moves premarket: Disney, Intel, Etsy, Fox Corp, Costco, Novartis & more",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "Novartis buys dry eye drug from Takeda for up to $5.3 billion",
            "features": {
                "keywords": [
                    "Novartis",
                    "Takeda",
                    "Dry",
                    "Eye",
                    "Drug"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis buys dry eye drug from Takeda for up to $5.3 billion",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-16",
            "original_text": "Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal",
            "features": {
                "keywords": [
                    "Novartis",
                    "Takeda",
                    "Eye",
                    "Drug",
                    "Assets"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novartis to Buy Takeda Eye Drug Assets in $5.3 Billion Deal",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "Takeda sheds products, 485 jobs in deals worth $5.7B",
            "features": {
                "keywords": [
                    "Takeda",
                    "Products",
                    "Jobs",
                    "Deals"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Takeda sheds products, 485 jobs in deals worth $5.7B",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-18",
            "original_text": "Takeda to sell eye drug to Novartis in $5.3bn deal",
            "features": {
                "keywords": [
                    "Takeda",
                    "Novartis",
                    "Eye",
                    "Drug",
                    "Deal"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Takeda to sell eye drug to Novartis in $5.3bn deal",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]